T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Apple Restores Telegram to App Store After Content Policy Violation 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Telegram Restored on Apple App Store After Temporary Removal 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
REDWOOD CITY, Calif., April 03, 2018 -- ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced that Martin Oft, M.D., Senior Vice President, Translational Medicine and Co-Founder, will participate in a panel presentation at the 8th Annual Cancer Immunotherapy Conference, taking place April 4-5 in New York City.
| Presentation Details: | ||||||||||||
| Date: | Wednesday, April 4 | |||||||||||
| Time: | 11:35am Eastern Time | |||||||||||
| Location: | Apella Event Space Alexandria Center, New York City | |||||||||||
| Topic: | Cytokines | |||||||||||
| Panelists: | Martin Oft, M.D., Senior Vice President, Translational Medicine and Co-Founder | |||||||||||
| ARMO BioSciences, Inc. | ||||||||||||
| Deborah Charych, Ph.D., Executive Director of Research & Development | ||||||||||||
| Nektar Therapeutics | ||||||||||||
About the 8th Annual Cancer Immunotherapy Conference
Hosted by William Blair and MaidStone Life Sciences, the annual cancer immunotherapy conference is a unique, two-day conference that brings together the founding scientists, leading clinicians, and pioneering biopharmaceutical companies driving the field of cancer immunotherapy. The agenda is designed to facilitate the exchange of information and highlight potential areas of opportunity for executives, investors, and others involved in transforming the future of cancer treatments. Each day will consist of a series of presentations from leading experts across the various disciplines in immuno-oncology followed by panel discussions to further elucidate key issues and paths forward.
About ARMO BioSciences
ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates that activate the immune system of cancer patients to recognize and eradicate tumors. The Company’s lead product candidate, AM0010 (pegilodecakin, PEGylated Interleukin-10), has demonstrated clinical benefit as a single agent, and in combination with both chemotherapy and checkpoint inhibitor therapy, across several tumor types. The drug is currently being investigated in a Phase 3 randomized pivotal clinical trial in pancreatic cancer patients. ARMO also has a number of other immuno-oncology product candidates in various stages of pre-clinical development including: AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, form of recombinant human Interleukin-15 (IL-15); and AM0012, a form of recombinant human Interleukin-12 (IL-12). For more information, please visit www.armobio.com.
CONTACTS:
ARMO BioSciences, Inc.
Herb Cross, Chief Financial Officer
650-241-3993
[email protected]
Dan Ferry
LifeSci Advisors, LLC
617-535-7746
